VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin
Status:
Completed
Trial end date:
2001-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I/II trial to study the effectiveness of VX-853 in treating patients who have
solid tumors who are receiving liposomal doxorubicin.